Neuland Laboratories Ltd - Stock Valuation and Financial Performance

BSE: 524558 | NSE: NEULANDLAB | Pharmaceuticals & Drugs | Small Cap

Neuland Laboratories Share Price

6,153.20 -199.50 -3.14%
as on 28-Mar'24 16:01

DeciZen - make an informed investing decision on Neuland Laboratories

Overall Rating
Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Semi Strong

Neuland Laboratories stock performance -

mw4me loader
P/E Ratio (SA):
25.46
Market Cap:
8,058.8 Cr.
52-wk low:
1,698.6
52-wk high:
7,450

Is Neuland Laboratories Ltd an attractive stock to invest in?

1. Is Neuland Laboratories Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Neuland Laboratories Ltd is a average quality company.

2. Is Neuland Laboratories Ltd undervalued or overvalued?

The key valuation ratios of Neuland Laboratories Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Neuland Laboratories Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Neuland Laboratories Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Neuland Laboratories:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Neuland Laboratories Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 14.9%10.8%12.1%11.2%3.2%3.4%3.4%8.9%7.4%16.3%-
Value Creation
Index
0.1-0.2-0.1-0.2-0.8-0.8-0.8-0.4-0.50.2-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 4664695105795276677639379511,1911,581
Sales YoY Gr.-0.7%8.7%13.5%-8.9%26.4%14.4%22.8%1.5%25.3%-
Adj EPS 36.518.529.353.113.815.513.156.850.6131.3246.7
YoY Gr.--49.2%58.1%81%-73.9%11.9%-15.5%334%-10.9%159.7%-
BVPS (₹) 151.8179206.3260273.5541.5549.2608.7650.6769.7940.8
Adj Net
Profit
29.316.526.147.212.319.916.872.864.9168317
Cash Flow from Ops. 48.513.144.738.911.569.656.618960.4239-
Debt/CF from Ops. 3.914.44.14.927.73.34.60.93.80.5-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 11%17.7%16%25.3%
Adj EPS 15.3%56.9%115.7%159.7%
BVPS19.8%23%11.9%18.3%
Share Price 38% 55.6% 44.9% 247.9%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
26.511.715.1132.23.22.49.8818.528.8
Op. Profit
Mgn %
15.914.415.718.59.69.513.515.915.223.730
Net Profit
Mgn %
6.33.55.18.22.332.27.86.814.120
Debt to
Equity
1.61.210.81.30.30.40.20.30.1-
Working Cap
Days
21124423322028424222520721819887
Cash Conv.
Cycle
73828710615212111610612311540

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 28.80%

Sales growth is growing at healthy rate in last 3 years 16.02%

Net Profit is growing at healthy rate in last 3 years 115.71%

Sales growth is good in last 4 quarters at 52.84%

No data to display

Latest Financials - Neuland Laboratories Ltd.

Standalone Consolidated
TTM EPS (₹) 246.7 247.1
TTM Sales (₹ Cr.) 1,581 1,581
BVPS (₹.) 940.8 945.7
Reserves (₹ Cr.) 1,194 1,200
P/BV 6.68 6.64
PE 25.46 25.42
From the Market
52 Week Low / High (₹) 1698.55 / 7450.00
All Time Low / High (₹) 14.26 / 7450.00
Market Cap (₹ Cr.) 8,059
Equity (₹ Cr.) 12.8
Face Value (₹) 10
Industry PE 48.2

Management X-Ray of Neuland Laboratories:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *4.304.300.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Neuland Laboratories

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales4664695105795276677639379511,191
Operating Expenses 395403430473477609661790809920
Manufacturing Costs59666271817798116131136
Material Costs247244253263238366380438422478
Employee Cost 3649608596104118144176195
Other Costs 534455556261659280111
Operating Profit 7066801065058101146142271
Operating Profit Margin (%) 15.1%14.1%15.7%18.3%9.5%8.7%13.3%15.6%15.0%22.8%
Other Income 312153416210
Interest 25272421191622181313
Depreciation 15151619222631404953
Exceptional Items 0000000000
Profit Before Tax 3424416714205210582215
Tax 8915202437251852
Profit After Tax 271626461216168064163
PAT Margin (%) 5.7%3.4%5.2%8.0%2.2%2.4%2.1%8.6%6.7%13.7%
Adjusted EPS (₹)33.317.829.752.213.312.612.462.649.5127.1
Dividend Payout Ratio (%)9%8%7%0%0%10%16%8%10%8%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 123160184232244696706782836988
Share Capital 899991313131313
Reserves 115151175223235683693769823975
Minority Interest0000000000
Debt17317916918130321024614519685
Long Term Debt3433453010361778810474
Short Term Debt140146124151199149168579211
Trade Payables931128689129124120157123178
Others Liabilities 946184383395101159240227328
Total Liabilities 4835115238851,0711,1301,2301,3241,3821,579

Fixed Assets

Gross Block259264292455483575714826913953
Accumulated Depreciation12814115319386492130166215
Net Fixed Assets131123139436445512623697748738
CWIP 3541402012610424172041
Investments 8888888741
Inventories93113127135175193220248265279
Trade Receivables119129119181194164190218234362
Cash Equivalents 76912173746181959
Others Assets9290829310611212011991100
Total Assets 4835115238851,0711,1301,2301,3241,3821,579

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 4913453912705718960239
PBT 3424416714205210582215
Adjustment 34363444403958406676
Changes in Working Capital -17-39-19-55-3916-4949-67-9
Tax Paid -3-9-12-16-3-5-5-5-21-44
Cash Flow From Investing Activity -10-14-20-42-116-77-49-84-96-61
Capex -11-15-19-41-133-63-48-105-98-65
Net Investments 10-1-115-16-61922
Others 0000115212
Cash Flow From Financing Activity -391-24010512-5-11438-136
Net Proceeds from Shares 0250001250000
Net Proceeds from Borrowing -28-916-579-3992223-33
Interest Paid -17-18-16-21-22-25-24-18-14-13
Dividend Paid -1-3-2-100-5-3-4-6
Others 75-222748-4914-11532-84
Net Cash Flow 001-3042-9341
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)24.3511.2515.4422.394.983.442.2710.817.8617.9
ROCE (%)18.9715.7418.4615.944.043.957.8412.839.4420.99
Asset Turnover Ratio1.050.9610.830.540.610.650.730.70.8
PAT to CFO Conversion(x)1.810.811.730.8514.383.562.360.941.47
Working Capital Days
Receivable Days839587931299885798791
Inventory Days7179858110710199919883
Payable Days129153143121167126117115121115

Neuland Laboratories Ltd Stock News

Neuland Laboratories Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Neuland Laboratories on 28-Mar-2024 16:01 is ₹6,153.2.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 28-Mar-2024 16:01 the market cap of Neuland Laboratories stood at ₹8,058.8.
The latest P/E ratio of Neuland Laboratories as of 28-Mar-2024 16:01 is 25.46.
The latest P/B ratio of Neuland Laboratories as of 28-Mar-2024 16:01 is 6.68.
The 52-week high of Neuland Laboratories is ₹7,450 and the 52-week low is ₹1,698.6.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Neuland Laboratories is ₹1,581 ( Cr.) .

About Neuland Laboratories Ltd

Named after Father Nieuwland of Notre dame, Neuland Laboratories was incorporated in 1984 by Dr. D. R. Rao for the manufacture of Salbutamol Sulphate, with mere 40 employees.

It has started its commercial production of Salbutamol Sulphate in the year 1986. It has since grown to become one of the most reliable API source for Pharma Industry with addition of more products in course of years.

Today the company with a total employee strength of 1000+ is the preferred supplier of APIs with unmatched quality and timely delivery. Neuland is a quality conscious, research driven, reliable source of active pharmaceutical ingredients.

Operating from India for over two decades, Neuland is the preferred source for the Pharmaceutical Industry across the globe, with strengths in Research based Chemistry and Manufacturing.

The Company has started its commercial production of Salbutamol Sulphate in the year 1986. It has since grown to become one of the most reliable API source for Pharma Industry with addition of more products in course of years.Today the company with a total employee strength of 1000+ is the preferred supplier of APIs with unmatched quality and timely delivery.

Neuland has two world-class API manufacturing facilities close to the city of Hyderabad, capable in handling complex and hazardous reactions. Safety aspects have been given utmost significance may it be plant installation, equipment, systems and personnel to ensure smooth productivity. Dedicated team of manufacturing with incorporation of latest production techniques guarantees delivery of latest intermediate and product to our customers across the globe.

Product range of the company includes:

  • Anti -Asthmatics
  • Fluoroquinolones
  • Cardiovascular
  • CNS
  • Corticosteroids
  • Anti-Ulcerant
  • Anti-Fungal
  • Anti-Parkinsons
  • Anti-Alzheimers

Achievements/ recognition:

  • Received a string of regulatory approvals from USFDA & EDQM for its major products (e.g., Ciprofloxacin HCl, Salbutamol Sulphate) USFDA systems inspection for its pashamylaram Facility (Unit-II) in the year 1999
  • USFDA systems inspection for its Bonthapally (Unit-I) bringing both facilities under full cGMP compliance in 2004
  • Received cGMP clearance for both facilities from TGA, Australia in 2004.
  • Certificate of suitability for product itraconazole in 2006.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.